189 related articles for article (PubMed ID: 27189816)
1. Validation of the 2014 European Society of Cardiology Sudden Cardiac Death Risk Prediction Model in Hypertrophic Cardiomyopathy in a Reference Center in South America.
Fernández A; Quiroga A; Ochoa JP; Mysuta M; Casabé JH; Biagetti M; Guevara E; Favaloro LE; Fava AM; Galizio N
Am J Cardiol; 2016 Jul; 118(1):121-6. PubMed ID: 27189816
[TBL] [Abstract][Full Text] [Related]
2. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy.
O'Mahony C; Tome-Esteban M; Lambiase PD; Pantazis A; Dickie S; McKenna WJ; Elliott PM
Heart; 2013 Apr; 99(8):534-41. PubMed ID: 23339826
[TBL] [Abstract][Full Text] [Related]
3. Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy.
Vriesendorp PA; Schinkel AF; Liebregts M; Theuns DA; van Cleemput J; Ten Cate FJ; Willems R; Michels M
Circ Arrhythm Electrophysiol; 2015 Aug; 8(4):829-35. PubMed ID: 25922410
[TBL] [Abstract][Full Text] [Related]
4. Validation of the 2014 European Society of Cardiology Sudden Cardiac Death Risk Prediction Model Among Various Phenotypes in Japanese Patients With Hypertrophic Cardiomyopathy.
Nakagawa S; Okada A; Nishimura K; Hamatani Y; Amano M; Takahama H; Amaki M; Hasegawa T; Kanzaki H; Kusano K; Yasuda S; Izumi C
Am J Cardiol; 2018 Dec; 122(11):1939-1946. PubMed ID: 30293654
[TBL] [Abstract][Full Text] [Related]
5. Predicting therapies in Japanese hypertrophic cardiomyopathy patients with an implantable cardioverter-defibrillator using the 2014 European Society of Cardiology guidelines.
Nakano M; Kondo Y; Nakano M; Kajiyama T; Miyazawa K; Hayashi T; Ito R; Takahira H; Kobayashi Y
Heart Vessels; 2021 Jan; 36(1):99-104. PubMed ID: 32666207
[TBL] [Abstract][Full Text] [Related]
6. [Feasibility of the 2014 European guidelines risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy in Chinese patients].
Zhu SH; Li Y; Huang W; Jiang H; Li SN; Chen L; Huang S; Yu HS; Xu B
Zhonghua Xin Xue Guan Bing Za Zhi; 2017 May; 45(5):404-408. PubMed ID: 28511325
[No Abstract] [Full Text] [Related]
7. International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM).
O'Mahony C; Jichi F; Ommen SR; Christiaans I; Arbustini E; Garcia-Pavia P; Cecchi F; Olivotto I; Kitaoka H; Gotsman I; Carr-White G; Mogensen J; Antoniades L; Mohiddin SA; Maurer MS; Tang HC; Geske JB; Siontis KC; Mahmoud KD; Vermeer A; Wilde A; Favalli V; Guttmann OP; Gallego-Delgado M; Dominguez F; Tanini I; Kubo T; Keren A; Bueser T; Waters S; Issa IF; Malcolmson J; Burns T; Sekhri N; Hoeger CW; Omar RZ; Elliott PM
Circulation; 2018 Mar; 137(10):1015-1023. PubMed ID: 29191938
[TBL] [Abstract][Full Text] [Related]
8. ESC sudden-death risk model in hypertrophic cardiomyopathy: Incremental value of quantitative contrast-enhanced CMR in intermediate-risk patients.
Hinojar R; Zamorano JL; Gonzalez Gómez A; Plaza Martin M; Esteban A; Rincón LM; Portugal JC; Jimenez Nácher JJ; Fernández-Golfín C
Clin Cardiol; 2017 Oct; 40(10):853-860. PubMed ID: 28614597
[TBL] [Abstract][Full Text] [Related]
9. Improvement in sudden cardiac death risk prediction by the enhanced American College of Cardiology/American Heart Association strategy in Chinese patients with hypertrophic cardiomyopathy.
Liu J; Wu G; Zhang C; Ruan J; Wang D; Zhang M; Wang L; Yang Y; Li X; Wang Y; Hui R; Zou Y; Kang L; Wang J; Song L
Heart Rhythm; 2020 Oct; 17(10):1658-1663. PubMed ID: 32311532
[TBL] [Abstract][Full Text] [Related]
10. Independent Assessment of the European Society of Cardiology Sudden Death Risk Model for Hypertrophic Cardiomyopathy.
Maron BJ; Casey SA; Chan RH; Garberich RF; Rowin EJ; Maron MS
Am J Cardiol; 2015 Sep; 116(5):757-64. PubMed ID: 26183790
[TBL] [Abstract][Full Text] [Related]
11. Cardiopulmonary exercise test and sudden cardiac death risk in hypertrophic cardiomyopathy.
Magrì D; Limongelli G; Re F; Agostoni P; Zachara E; Correale M; Mastromarino V; Santolamazza C; Casenghi M; Pacileo G; Valente F; Musumeci B; Maruotti A; Volpe M; Autore C
Heart; 2016 Apr; 102(8):602-9. PubMed ID: 26849900
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Role of Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Low-to-Intermediate Sudden Cardiac Death Risk Score.
Todiere G; Nugara C; Gentile G; Negri F; Bianco F; Falletta C; Novo G; Di Bella G; De Caterina R; Zachara E; Re F; Clemenza F; Sinagra G; Emdin M; Aquaro GD
Am J Cardiol; 2019 Oct; 124(8):1286-1292. PubMed ID: 31447011
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: A systematic review and meta-analysis.
Norrish G; Cantarutti N; Pissaridou E; Ridout DA; Limongelli G; Elliott PM; Kaski JP
Eur J Prev Cardiol; 2017 Jul; 24(11):1220-1230. PubMed ID: 28482693
[TBL] [Abstract][Full Text] [Related]
14. Validation of the HCM Risk-SCD model in patients with hypertrophic cardiomyopathy following alcohol septal ablation.
Liebregts M; Faber L; Jensen MK; Vriesendorp PA; Hansen PR; Seggewiss H; Horstkotte D; Adlova R; Michels M; Bundgaard H; Ten Berg JM; Veselka J
Europace; 2018 Sep; 20(FI2):f198-f203. PubMed ID: 29016960
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the new risk prediction model (HCM Risk-SCD) and classic risk factors for sudden death in patients with hypertrophic cardiomyopathy and defibrillator.
Ruiz-Salas A; García-Pinilla JM; Cabrera-Bueno F; Fernández-Pastor J; Peña-Hernández J; Medina-Palomo C; Barrera-Cordero A; De Teresa E; Alzueta J
Europace; 2016 May; 18(5):773-7. PubMed ID: 25855675
[TBL] [Abstract][Full Text] [Related]
16. Implantable cardioverter defibrillators for primary prevention of sudden death in hypertrophic cardiomyopathy.
Konstantinou DM; Efthimiadis GK; Vassilikos V; Paraskevaidis S; Pagourelias E; Maron BJ; Karvounis H
J Cardiovasc Med (Hagerstown); 2016 Jun; 17(6):433-9. PubMed ID: 26885981
[TBL] [Abstract][Full Text] [Related]
17. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.
Syska P; Przybylski A; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Gepner K; Pytkowski M; Kowalik I; Maczyńska-Mazuruk R; Ruzyłło W; Szwed H
J Cardiovasc Electrophysiol; 2010 Aug; 21(8):883-9. PubMed ID: 20132378
[TBL] [Abstract][Full Text] [Related]
18. A validation study of the European Society of Cardiology guidelines for risk stratification of sudden cardiac death in childhood hypertrophic cardiomyopathy.
Norrish G; Ding T; Field E; McLeod K; Ilina M; Stuart G; Bhole V; Uzun O; Brown E; Daubeney PEF; Lota A; Linter K; Mathur S; Bharucha T; Kok KL; Adwani S; Jones CB; Reinhardt Z; Omar RZ; Kaski JP
Europace; 2019 Oct; 21(10):1559-1565. PubMed ID: 31155643
[TBL] [Abstract][Full Text] [Related]
19. QRS Fragmentation and QTc Duration Relate to Malignant Ventricular Tachyarrhythmias and Sudden Cardiac Death in Patients with Hypertrophic Cardiomyopathy.
Debonnaire P; Katsanos S; Joyce E; VAN DEN Brink OV; Atsma DE; Schalij MJ; Bax JJ; Delgado V; Marsan NA
J Cardiovasc Electrophysiol; 2015 May; 26(5):547-55. PubMed ID: 25648421
[TBL] [Abstract][Full Text] [Related]
20. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy.
Vieira AP; Adragão PP; Santos KR; Morgado FB; Cavaco DM; Rossi R; Abecasis M; Neves JP; Bonhosrst D; Gomes JL; Gomes RS
Rev Port Cardiol; 2005 Mar; 24(3):407-15. PubMed ID: 15929624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
